![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs15033-023-3535-z/MediaObjects/15033_2023_3535_Fig1_HTML.jpg)
Literatur
Nathan SD, Noble P, Tuder R. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med. 2007;175:875-80
Simonneau G, Montani D, Celermajer DS et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913
Humbert M, Kovacs G, Hoeper MM et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-731
Nathan SD, Waxman A, Rajagopal S et al. Inhaled treprostinil and FVC change in patients with interstitial lung disease and associated pulmonary hypertension. Lancet Respir Med. 2021;9:1266-74
van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis. 2022;16:17534666221117002
Copeland CR, Lancaster LH. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Front Med (Lausanne). 2021;8:743977
Polke M, Herth FJF. Krankheitsverlauf kann verlangsamt werden. Immer besser therapierbar: Lungenfibrosen. MMW Fortschr Med. 2023;165(Suppl 1):36-8
Suzuki A, Kondoh Y, Brown KK et al. Acute exacerbations of fibrotic interstitial lung diseases. 2020;25(5):525-34
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gillissen, A. Wie sinnvoll ist die Senkung des pulmonal-arteriellen Druckes?. Pneumo News 15, 12–13 (2023). https://doi.org/10.1007/s15033-023-3535-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15033-023-3535-z